While media attention has focused on the availability of abortions, take note: contradictory court decisions about mifepristone broadly threaten the authority of the Food and Drug Administration (FDA) to approve and regulate new medications for any indication.

The U.S. Senate passed the Inflation Reduction Act on Sunday, with Vice President Kamala Harris casting the tie-breaking vote to settle the verdict, which was split 50-50 along party lines. The bill, which is expected to have wide-ranging implications for the pharmaceutical industry, will still need to go to the House of Representatives, but with a Democratic majority, it is expected to pass before the end of the week.